Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model.

Chih-Hung Guo, Wen-Chin Li, Chia-Lin Peng, Pei-Chung Chen, Shih-Yu Lee, Simon Hsia

Open access · goldAbstract read

In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.4field-weighted citation impact, top 36% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

The Effects and Mechanisms of the YY1/EGFR Axis on Inflammation and Oxidative Stress in Asthma.Cell biochemistry and biophysics · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chih-Hung GuoMicronutrition and Biomedical Nutrition Laboratories, Institute of Biomedical Nutrition, Hung-Kuang University, Taichung 433, Taiwan.

Wen-Chin LiTaiwan Nutraceutical Association, Taipei 105, Taiwan.

Chia-Lin PengTaiwan Nutraceutical Association, Taipei 105, Taiwan.

Pei-Chung ChenTaiwan Nutraceutical Association, Taipei 105, Taiwan.

Shih-Yu LeeBiotechnology, Health, and Innovation Research Center, Hung-Kuang University, Taichung 433, Taiwan.

Simon HsiaTaiwan Nutraceutical Association, Taipei 105, Taiwan.

Taiwan Nurses Association · TWHungkuang University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selenium (Se) and fish oil (FO) exert anti-epidermal growth factor receptor (EGFR) action on tumors. This study aimed to compare the anti-cancer efficacy of EGFR inhibitors (gefitinib and erlotinib) alone and in combination with nutritional supplements of Se/FO in treating lung cancer. Lewis LLC1 tumor-bearing mice were treated with a vehicle or Se/FO, gefitinib or gefitinib plus Se/FO, and erlotinib or erlotinib plus Se/FO. The tumors were assessed for mRNA and protein expressions of relevant signaling molecules. Untreated tumor-bearing mice had the lowest body weight and highest tumor weight and volume of all the mice. Mice receiving the combination treatment with Se/FO and gefitinib or erlotinib had a lower tumor volume and weight and fewer metastases than did those treated with gefitinib or erlotinib alone. The combination treatment exhibited greater alterations in receptor signaling molecules (lower EGFR/TGF-β/TβR/AXL/Wnt3a/Wnt5a/FZD7/β-catenin; higher GSK-3β) and immune checkpoint molecules (lower PD-1/PD-L1/CD80/CTLA-4/IL-6; higher NKp46/CD16/CD28/IL-2). These mouse tumors also had lower angiogenesis, cancer stemness, epithelial to mesenchymal transitions, metastases, and proliferation of Ki-67, as well as higher cell cycle arrest and apoptosis. These preliminary results showed the Se/FO treatment enhanced the therapeutic efficacies of gefitinib and erlotinib via modulating multiple signaling pathways in an LLC1-bearing mouse model.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Lewis LungDietary SupplementsErbB ReceptorsErlotinib HydrochlorideFish OilsGefitinibProtein Kinase InhibitorsSeleniumAnimalsGlycogen Synthase Kinase 3 betaMiceErbB ReceptorsErlotinib HydrochlorideFish OilsGefitinibGlycogen Synthase Kinase 3 betaProtein Kinase InhibitorsSeleniumanti-tumor signaling pathwayerlotinibfish oilgefitinibLewis lung carcinomamiceselenium

Identifiers

PMID36547898

DOI10.3390/md20120751

PMCPMC9783964

OpenAlexW4310382691

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.